Supplementary Table 1 from Somatic <i>ERCC2</i> Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma

Treatment information and sequencing metrics for all patients The treatment information and raw sequencing metrics, including mean target coverage, for each case is listed here. In addition, the mutation rate data referred to in the Results and represented in Supplementary Figure 1 is listed here by synonymous rate, non-synonymous rate, and total number of mutations per patient. *Cases that were included in the TCGA effort (UC-0296 and UC-0234). (dd = dose dense, GC = gemcitabine/cisplatin, MVAC = methotrexate, vinblastine, doxorubicin, cisplatin). Unavailable cases for Fluidigm Validation (due to inadequate remaining DNA or technical failure) are also denoted (n = 15).所有患者的治疗信息与测序指标 本列表收录了每一例病例的治疗信息与原始测序指标，其中包含平均靶区域覆盖度（mean target coverage）。此外，本研究结果中提及并在补充图1中展示的突变率数据亦在此列出，按同义突变率、非同义突变率及每例患者的总突变数分类呈现。 * 纳入癌症基因组图谱（TCGA）项目的病例（UC-0296与UC-0234）。（注：dd=剂量密集型方案；GC=吉西他滨/顺铂联合方案；MVAC=甲氨蝶呤、长春碱、多柔比星、顺铂联合化疗方案）。因剩余DNA不足或技术故障无法完成Fluidigm验证的病例已予以标注（n=15）。